GD2-C7R T cells

GD2-C7R T cells are an autologous chimeric antigen receptor (CAR) T-cell therapy engineered to target the disialoganglioside GD2, a surface antigen highly expressed on neuroblastoma, sarcomas, and certain brain tumors. In addition to the GD2-specific CAR, these cells are modified with a gene called C7R, which encodes a constitutively active interleukin-7 (IL-7) receptor signal. The inclusion of C7R is designed to provide the T cells with a continuous survival and expansion signal, mimicking the effect of the cytokine IL-7, thereby enhancing their persistence and anti-tumor activity within the immunosuppressive tumor microenvironment without the need for exogenous cytokine administration. The therapy is being developed primarily by the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital.

Other names

C7R-GD2.CAR T cellsC-7R-GD2.CAR T cellsC 7R-GD2.CAR T cellsGD2.C7R T cellsGD-2.C7R T cellsGD 2.C7R T cellsautologous GD2-C7R CAR-T cellsGAIL-NGAIL-B